Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20805858 | 0.83 | KDM4E (0.37) | KDM4E | |
| SCHEMBL3079552 | 0.75 | GABRA1 (0.52) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL22538428 | 0.72 | GABRA1 (0.39) | GABRA1GABRB2 | |
| SCHEMBL19734035 | 0.72 | LMNA (0.48) | KDM4E | |
| SCHEMBL9064418 | 0.69 | GABRA1 (0.46) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL19320484 | 0.67 | TYR (0.49) | KDM4E | |
| SCHEMBL20285914 | 0.66 | GABRA1 (0.43) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL22130540 | 0.64 | GABRA1 (0.41) | GABRA1GABRB2KDM4E | |
| SCHEMBL2830370 | 0.64 | GABRA1 (0.50) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL17118300 | 0.63 | FABP4 (0.48) | GABRA1GABRB2FABP3FABP4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | GABRA1 3538/4885GABRB2 2596/4885FABP3 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.